HRTX Stock Summary and Trading Ideas (Heron Therapeutics | NASDAQ:HRTX)

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Heron Therapeutics trades on the NASDAQ stock market under the symbol HRTX.

As of January 23, 2026, HRTX stock price declined to $1.42 with 1,059,348 million shares trading.

HRTX has a beta of 0.87, meaning it tends to be less sensitive to market movements. HRTX has a correlation of 0.05 to the broad based SPY ETF.

HRTX has a market cap of $260.31 million. This is considered a Small Cap stock.

Last quarter Heron Therapeutics reported $38 million in Revenue and -$.04 earnings per share. This fell short of revenue expectation by $-633,750 and missed earnings estimates by -$.02.

In the last 3 years, HRTX traded as high as $3.93 and as low as $.50.

The top ETF exchange traded funds that HRTX belongs to (by Net Assets): VTI, IWM, VXF, IWN, SCHA.

HRTX has underperformed the market in the last year with a return of -19.3%, while SPY returned +14.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HRTX shares. However, HRTX has outperformed the market in the last 3 month and 2 week periods, returning +19.3% and +2.2%, while SPY returned +2.9% and -0.7%, respectively. This indicates HRTX has been having a stronger performance recently.

HRTX support price is $1.39 and resistance is $1.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HRTX shares will trade within this expected range on the day.